Grantham, Mayo, Van Otterloo & Co (GMO)
LRMR icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s Larimar Therapeutics LRMR Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,065
Closed -$58.8K – 698
2026
Q1 		$58.8K Buy
+13,065
New +$52.2K ﹤0.01% 624

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s LRMR Position: Q2 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Larimar Therapeutics (LRMR) in Q2 2026, closing a stake of 13,065 shares — an estimated $58.8K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in LRMR in Q1 2026 and held it in 1 quarter. The position peaked at $58.8K in Q1 2026. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Larimar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 13,065 Larimar Therapeutics shares in Q2 2026, an estimated $58.8K.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Larimar Therapeutics in Q1 2026 and held it in 1 quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Larimar Therapeutics position peaked at $58.8K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2026, filed 13 Aug 2026.